Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Zumpano

Internal Medicine Branford, CT Medical Doctor

NPI 1437141363 CMS profile 489461

144 N Main St, Branford, CT 06405

Open in the dashboard

General payments

$2,195

113 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, James Zumpano of Branford, CT is reported in the CMS Open Payments database as having received $2,195 across 113 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $428 21
2024 General $398 22
2023 General $490 26
2022 General $325 18
2021 General $119 7
2020 General $219 6
2019 General $216 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Zumpano
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to James Zumpano were reported at $428. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year James Zumpano Internal Medicine median Middle half National median
2019 $216 $159 $48–$570 $163
2020 $219 $119 $33–$402 $114
2021 $119 $135 $37–$521 $132
2022 $325 $141 $42–$496 $149
2023 $490 $149 $45–$519 $160
2024 $398 $154 $47–$537 $164
2025 $428 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lilly USA, LLC $313 16 payments
  2. GlaxoSmithKline, LLC. $260 6 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $225 12 payments
  4. AstraZeneca Pharmaceuticals LP $164 11 payments
  5. Novo Nordisk Inc $160 10 payments
  6. Astellas Pharma US Inc $146 6 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $132 7 payments
  8. Exact Sciences Corporation $126 6 payments
  9. Lundbeck LLC $113 7 payments
  10. Novartis Pharmaceuticals Corporation $91 5 payments
  11. Other $465 27 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,125 111 payments
  2. Education $70 2 payments
Products named General payments · program years 2019–2025
  1. ZEPBOUND $169 8 payments
  2. FARXIGA $146 10 payments
  3. MOUNJARO $144 7 payments
  4. XIFAXAN $132 7 payments
  5. Cologuard Collection Kit $126 6 payments
  6. TRELEGY ELLIPTA $124 1 payment
  7. JARDIANCE Diabetes $123 7 payments
  8. REXULTI $113 7 payments
  9. JARDIANCE Diabetes $110 6 payments
  10. SHINGRIX $96 3 payments
  11. Other $1,348 73 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 146 drugs

Part D claims

8,646

Median for Internal Medicine: 777

Drug cost

$600,170

Median for Internal Medicine: $73,373

Branded share of claims

19.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 319 $126,718
Farxiga Dapagliflozin Propanediol Brand 76 $86,219
Jardiance Empagliflozin Brand 53 $54,354
Ozempic Semaglutide Brand 31 $50,798
Xarelto Rivaroxaban Brand 75 $23,327
Rexulti Brexpiprazole Brand 30 $21,206
Briviact Brivaracetam Brand 23 $15,991
Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog Brand 32 $11,063
Lagevrio (Eua) Molnupiravir Brand 13 $9,506
Linzess Linaclotide Brand 16 $9,099

The 10 drugs with the highest cost, of 146 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$100,995

Of which drugs: $4,558

Medicare patients

336

Average age 79

Services billed

1,317

178 women, 158 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Depression 45%
Ischemic heart disease 44%
Chronic kidney disease 42%
Heart failure 38%
Alzheimer's or dementia 37%
Diabetes 35%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 52 52 $4,255

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $48
  • Lilly USA, LLC $45
$93 53 —
REXULTI
  • Lundbeck LLC $47
$47 30 —
VRAYLAR
  • AbbVie, Inc. $46
$46 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $30
$30 — —
ZEPBOUND
  • Lilly USA, LLC $29
$29 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

113 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record